Daymark Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Daymark Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$720K	Sell	5,076 -169	-3%	-$27.2K	0.02%	422
2026 Q2	$884K	Buy	5,245 +28	+0.5%	+$4.15K	0.02%	359
2026 Q1	$687K	Buy	5,217 +3,436	+193%	+$456K	0.02%	355
2025 Q4	$253K	Sell	1,781 -127	-7%	-$18.4K	0.01%	530
2025 Q3	$268K	Sell	1,908 -37	-2%	-$5.01K	0.01%	510
2025 Q2	$244K	Buy	+1,945	New	+$223K	0.01%	493
2025 Q1	–	Sell	-1,786	Closed	-$244K	–	520
2024 Q4	$244K	Buy	+1,786	New	+$221K	0.01%	450
2024 Q3	–	Sell	-1,774	Closed	-$244K	–	523
2024 Q2	$244K	Buy	1,774 +274	+18%	+$37.6K	0.01%	444
2024 Q1	$207K	Buy	+1,500	New	+$205K	0.01%	412

Other funds holding NBIX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Daymark Wealth Partners's NBIX Position: Q3 2026 in Review

Daymark Wealth Partners reduced its Neurocrine Biosciences (NBIX) stake by 3.2% in Q3 2026, selling an estimated $27.2K and leaving 5,076 shares worth $720K. The position accounts for 0.02% of the portfolio, ranked #422.

Daymark Wealth Partners first reported a position in NBIX in Q1 2024 and has held it in 9 quarters since. The position peaked at $884K in Q2 2026. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Daymark Wealth Partners held 5,076 shares of Neurocrine Biosciences worth $720K as of Q3 2026.
Daymark Wealth Partners sold 169 Neurocrine Biosciences shares in Q3 2026, an estimated $27.2K.
Neurocrine Biosciences made up 0.02% of Daymark Wealth Partners's portfolio in Q3 2026, its #422 holding.
Daymark Wealth Partners first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 9 quarters since.
Daymark Wealth Partners's Neurocrine Biosciences position peaked at $884K in Q2 2026.
630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Daymark Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.